Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug.
about
Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databasesTNF inhibitor therapy for rheumatoid arthritis[Switching within the active ingredient group or changing the mechanism of action. Data situation by failure of the first line biologic].Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients: clues for the pathogenesis.DAS-28-based EULAR response and HAQ improvement in rheumatoid arthritis patients switching between TNF antagonistsCost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting.The predictive value of serum S100A9 and response to etanercept is not confirmed in a large UK rheumatoid arthritis cohort.MicroRNA-34a dependent regulation of AXL controls the activation of dendritic cells in inflammatory arthritisThe impact of patient-perceived restricted access to anti-TNF therapy for rheumatoid arthritis: a qualitative study.Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies.The effectiveness of anti-TNF-alpha therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysisThresholds in disease activity for switching biologics in rheumatoid arthritis patients: experience from a large U.S. cohort.Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitorsGreater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the Consortium of Rheumatology Researchers of North America registryRituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register.Rheumatoid arthritis treatment with TNF inhibitors and alternative procedures in case of its failure - results of the Polish survey in the context of EULAR recommendationsTreatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical reviewThe BSRBR-RA at 15 years.Certolizumab in the long-term treatment of rheumatoid arthritis.Use of Bayesian multivariate meta-analysis to estimate the HAQ for mapping onto the EQ-5D questionnaire in rheumatoid arthritis.Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment.Epidemiology and Treatment of New-Onset and Established Rheumatoid Arthritis in an Insured US Population.Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry.
P2860
Q26778600-E22C8DB1-E289-41D3-8B47-5147B549CF8EQ28972424-C34AB940-1DAB-4B07-ABB1-68C054317F3FQ30962462-3B1C29B3-E7B8-4016-8C13-407798C16DDBQ31078960-383FAD2A-5E7C-4FD7-9EF7-0DC89506A164Q33486150-AF8B4D0E-9AA5-4967-B3EA-823ECE481E39Q33726931-00DF6548-6B9A-4900-89AD-F6CB2A8D9F41Q33731299-FBF310DD-7CE4-4B15-81C5-B7551D18E8DCQ33849824-D3F52CE0-F932-40CD-B960-D240B49D17B9Q33918359-F44BE19F-3D31-431C-B4FE-6D5470EACDF5Q34017619-6A64591F-8A1E-4868-AD0D-7D0F84D8EFA4Q34315535-677DFFB7-D65B-4D45-9C32-42AA12C3EE62Q35583230-AFDE00C7-E700-45C3-9061-C11435FACD76Q35620336-D8D0472D-EFE8-4F31-BCA1-7CE6D7944D23Q36024297-E52A966E-A65E-4ACD-956D-3A3E7964DC54Q36382724-8DDE8CAD-0EAD-449C-8D39-E43113C4745AQ36842389-03CD2F62-F74C-4895-9A83-A5F848EE9F4AQ37158791-F67F1476-1CE4-49A4-8B3E-24DEECB35D1EQ37333943-25C83D29-2A32-420F-8292-8F41D015326EQ37358254-FD3D3659-B8C8-44E1-B4D4-41A5C7D9A1FCQ37572857-F87C1A76-99C4-4140-A132-505F6518536FQ37786627-D9A23AC2-6EF3-4B7B-8C95-D59B3CC62C40Q38020460-3B9FECE4-0F00-4117-B33A-9414E5F9AE32Q40813632-868E6115-FD98-4FD1-B3F3-BA2D22970829Q45229094-799DFD22-4F75-4548-8812-14247B6C0A1C
P2860
Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Effects of switching between a ...... to their first anti-TNF drug.
@ast
Effects of switching between a ...... to their first anti-TNF drug.
@en
type
label
Effects of switching between a ...... to their first anti-TNF drug.
@ast
Effects of switching between a ...... to their first anti-TNF drug.
@en
prefLabel
Effects of switching between a ...... to their first anti-TNF drug.
@ast
Effects of switching between a ...... to their first anti-TNF drug.
@en
P2093
P2860
P50
P356
P1433
P1476
Effects of switching between a ...... d to their first anti-TNF drug
@en
P2093
BSR Biologics Register
K D Watson
K L Hyrich
P2860
P304
P356
10.1093/RHEUMATOLOGY/KEN127
P577
2008-04-17T00:00:00Z